AbstractWe reported previously on a vaccine approach that conferred apparent sterilizing immunity to SIVsmE660. The vaccine regimen employed a prime–boost using vectors based on recombinant vesicular stomatitis virus (VSV) and an alphavirus replicon expressing either SIV Gag or SIV Env. In the current study, we tested the ability of vectors expressing only the SIVsmE660 Env protein to protect macaques against the same high-dose mucosal challenge. Animals developed neutralizing antibody levels comparable to or greater than seen in the previous vaccine study. When the vaccinated animals were challenged with the same high-dose of SIVsmE660, all became infected. While average peak viral loads in animals were slightly lower than those of previou...
The suppression of viral loads and identification of selection signatures in non-human primates afte...
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targetin...
In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vecto...
AbstractWe reported previously on a vaccine approach that conferred apparent sterilizing immunity to...
We compared the efficacy of immunization with either simian immunodeficiency virus (SIV) Env glycopr...
Attempts to develop a protective human immunodeficiency virus (HIV) vaccine have had limited success...
The RV144 vaccine trial in Thailand demonstrated that an HIV vaccine could prevent infection in huma...
<div><p>The ability to control lentivirus replication may be determined, in part, by the extent to w...
Conventional HIV T cell vaccine strategies have not been successful in containing acute peak viremia...
All human immunodeficiency virus (HIV) vaccine efficacy trials to date have ended in failure. Struct...
International audienceAbstract Replicative vectors derived from live-attenuated measles virus (MV) c...
AbstractThree Indian rhesus macaques, Ad-SIV primed/protein boosted and exposed twice to high-dose m...
Given the current difficulties generating vaccine-induced neutralizing antibodies to human immunodef...
The lack of an effective HIV vaccine calls for efforts to investigate the mechanism of protective im...
Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immuno...
The suppression of viral loads and identification of selection signatures in non-human primates afte...
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targetin...
In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vecto...
AbstractWe reported previously on a vaccine approach that conferred apparent sterilizing immunity to...
We compared the efficacy of immunization with either simian immunodeficiency virus (SIV) Env glycopr...
Attempts to develop a protective human immunodeficiency virus (HIV) vaccine have had limited success...
The RV144 vaccine trial in Thailand demonstrated that an HIV vaccine could prevent infection in huma...
<div><p>The ability to control lentivirus replication may be determined, in part, by the extent to w...
Conventional HIV T cell vaccine strategies have not been successful in containing acute peak viremia...
All human immunodeficiency virus (HIV) vaccine efficacy trials to date have ended in failure. Struct...
International audienceAbstract Replicative vectors derived from live-attenuated measles virus (MV) c...
AbstractThree Indian rhesus macaques, Ad-SIV primed/protein boosted and exposed twice to high-dose m...
Given the current difficulties generating vaccine-induced neutralizing antibodies to human immunodef...
The lack of an effective HIV vaccine calls for efforts to investigate the mechanism of protective im...
Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immuno...
The suppression of viral loads and identification of selection signatures in non-human primates afte...
HIV mutates rapidly and infects CD4+ T cells, especially when they are activated. A vaccine targetin...
In previous work, a prototypic recombinant vesicular stomatitis virus Indiana serotype (rVSIV) vecto...